Using Top-down and Bottom-up Costing Approaches in LMICs: The Case for Using Both to Assess the Incremental Costs of New Technologies at Scale

Health Economics (United Kingdom)

Volumn 25, Issue , 2016, Pages 53-66

  Cunnama, Lucy ^a   Sinanovic, Edina ^a   Ramma, Lebogang ^a   Foster, Nicola ^a   Berrie, Leigh ^b   Stevens, Wendy ^b   Molapo, Sebaka ^b   Marokane, Puleng ^b   McCarthy, Kerrigan ^c   Churchyard, Gavin ^c,d,e   Vassall, Anna ^e  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b NATIONAL HEALTH LABORATORY SERVICE   (South Africa)

^c AURUM INSTITUTE   (South Africa)

^d UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^e LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

cost analysis; diagnostics; economies of scale; LMICs; scale up; tuberculosis

Indexed keywords

RIFAMPICIN;

ANTIBIOTIC RESISTANCE; ARTICLE; COST BENEFIT ANALYSIS; HEALTH CARE COST; LOWEST INCOME GROUP; MICROSCOPY; MIDDLE INCOME GROUP; MYCOBACTERIUM TUBERCULOSIS TEST KIT; PRIORITY JOURNAL; RAPID TEST; SOCIOECONOMICS; SOUTH AFRICA; BIOMEDICAL TECHNOLOGY ASSESSMENT; DEVELOPING COUNTRY; ECONOMICS; HUMAN; INVENTION; ISOLATION AND PURIFICATION; MYCOBACTERIUM TUBERCULOSIS; STATISTICAL ANALYSIS; TUBERCULOSIS, PULMONARY;

COST-BENEFIT ANALYSIS; DATA INTERPRETATION, STATISTICAL; DEVELOPING COUNTRIES; HEALTH CARE COSTS; HUMANS; INVENTIONS; MYCOBACTERIUM TUBERCULOSIS; SOUTH AFRICA; TECHNOLOGY ASSESSMENT, BIOMEDICAL; TUBERCULOSIS, PULMONARY;

EID: 84956573738     PISSN: 10579230     EISSN: 10991050     Source Type: Journal    
DOI: 10.1002/hec.3295     Document Type: Article

References (33)

1. Adam T, et al., 2008. Capacity utilization and the cost of primary care visits: Implications for the costs of scaling up health interventions. Cost effectiveness and resource allocation 6: 1-9. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2628647&tool=pmcentrez&rendertype=abstract [Accessed September 26, 2014].
2. Batura N, et al., 2014. Collecting and analysing cost data for complex public health trials: reflections on practice. Global Health Action 7: 1-9.
3. Chapko MK, et al., 2009. Equivalence of two healthcare costing methods: Bottom-up and top-down. Health Economics 18: 1188-1201.
4. Churchyard G,. 2014. Effect of Xpert MTB/RIF on early mortality in adults with suspected TB: a pragmatic randomized trial. In 21st Conference on Retroviruses and Opportunistic Infections, 3-6 March 2014, Oral Abstract 95. Boston. Available at: http://www.croiwebcasts.org/console/player/22178 [Accessed October 27, 2015].
5. Churchyard G, 2011. "Xpert for TB: Evaluating a new diagnostic" (EXTEND) trial, Johannesburg.
6. Churchyard GJ, et al., 2015. Xpert MTB/RIF versus sputum microscopy as the initial diagnostic test for tuberculosis: a cluster-randomised trial embedded in South African roll-out of Xpert MTB/RIF. Lancet Global Health 3: 450-457. Available at: http://ac.els-cdn.com/S2214109X1500100X/1-s2.0-S2214109X1500100X-main.pdf?-tid=a91481a4-400e-11e5-b663-00000aab0f6c&acdnat=1439286921-17664dd8fc375f35c6fa79a0cc830651 [Accessed October 27, 2015].
7. Conteh L, Walker D,. 2004. Cost and unit cost calculations using step-down accounting. Health Policy and Planning 19 (2): 127-135. Available at: http://www.heapol.oupjournals.org/cgi/doi/10.1093/heapol/czh015 [Accessed March 24, 2014].
8. Drummond M, et al., 1997. Methods for the Economic Evaluation of Health Care Programmes (2nd edn), Oxford University Press: New York, United States of America.
9. Flessa S, et al., 2011. Basing care reforms on evidence: the Kenya health sector costing model. BMC Health Services Research 11 (128): 1-15. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3129293&tool=pmcentrez&rendertype=abstract [Accessed October 27, 2015].
10. Futures Institute. 2014. OneHealth Tool. Available at: http://www.futuresinstitute.org/onehealth.aspx [Accessed October 27, 2015].
11. Gilson L, Schneider H,. 2010. Commentary: managing scaling up: What are the key issues? Health Policy and Planning 25 (2): 97-98.
12. Health Systems Trust. 2012. National Health Laboratory Service still struggling with tardy provincial payments.
13. Hendriks ME, et al., 2014. Step-by-step guideline for disease-specific costing studies in low-and middle-income countries: a mixed methodology. Global Health Action 7: 1-10.
14. Koh GCKW, et al., 2013. Tuberculosis Incidence Correlates with Sunshine: an Ecological 28-Year Time Series Study. PLoS ONE 8 (3): 1-5.
15. Lépine A, et al., 2015. Estimating unbiased economies of scale of HIV prevention projects: a case study of Avahan. Social Science & Medicine 131: 164-72. Available at: http://www.ncbi.nlm.nih.gov/pubmed/25779621 [Accessed October 27, 2015].
16. Menzies N, Cohen T, et al., 2012a. Population health impact and cost-effectiveness of tuberculosis diagnosis with Xpert MTB/RIF: a dynamic simulation and economic evaluation. PLoS Medicine 9 (11): 1-17. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3502465&tool=pmcentrez&rendertype=abstract [Accessed March 24, 2014].
17. Menzies N, Berruti A, Blandford J,. 2012b. The Determinants of HIV Treatment Costs in Resource Limited Settings. PLoS ONE 7 (11): 1-19.
18. Mercier G, Naro G,. 2014. Costing hospital surgery services: The method matters. PLoS One 9 (5): 1-7. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4016301&tool=pmcentrez&rendertype=abstract [Accessed November 6, 2014].
19. Molapo S,. 2013. E-mail to Lucy Cunnama (nee Shillington) 10 September.
20. National Department of Health. 2014. National Tuberculosis Management Guidelines, Pretoria, South Africa. Available at: http://www.sahivsoc.org/upload/documents/NTCP-Adult-TBGuidelines 27.5.2014.pdf [Accessed October 27, 2015].
21. National Health Laboratory Service. 2013. GeneXpert MTB/RIF Progress report, Available at: http://www.nhls.ac.za/assets/files/GeneXpert Progress Report August 2013-Final.pdf [Accessed October 27, 2015].
22. Simoens S,. 2009. Health economic assessment: a methodological primer. International Journal of Environmental Research and Public Health 6 (12): 2950-66. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2800325&tool=pmcentrez&rendertype=abstract [Accessed November 10, 2014].
23. Steingart K, et al., 2014. Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults. Cochrane Database Systematic Review, Issue(1): 1-166. Available at: http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009593.pub3/pdf/standard [Accessed March 18, 2014].
24. Tagar E, et al., 2014. Multi-Country Analysis of Treatment Costs for HIV/AIDS (MATCH): Facility-Level ART Unit Cost Analysis in Ethiopia, Malawi, Rwanda, South Africa and Zambia. PLoS Medicine 9 (11): 1-9.
25. Treatment action campaign. 2014. NHLS oversight in crisis-patients pay the price. Available at: http://www.tac.org.za/news/nhls-oversight-crisis-patients-pay-price [Accessed August 12, 2015].
26. UNAIDS. 2011. Manual for costing HIV facilities and services. Available at: http://www.unaids.org/en/media/unaids/contentassets/documents/document/2011/20110523-manual-costing-HIV-facilities-en.pdf [Accessed October 27, 2015].
27. Vassall, A., Sinanovic, E, et al., 2011a. Evaluating the cost of scaling up Xpert MTB/RIF in the investigation of tuberculosis in South Africa, Johannesburg.
28. Vassall, A., van Kampen, S, et al., 2011b. Rapid diagnosis of tuberculosis with the Xpert MTB/RIF assay in high burden countries: a cost-effectiveness analysis. D. Wilson, ed. PLoS Medicine 8 (11): 1-14. Available at: http://dx.plos.org/10.1371/journal.pmed.1001120 [Accessed March 22, 2014].
29. Wordsworth S, et al., 2005. Collecting unit cost data in multicentre studies: Creating comparable methods. The European Journal of Health Economics 50 (1): 38-44. Available at: http://www.ncbi.nlm.nih.gov/pubmed/15772871 [Accessed November 20, 2014].
30. World Health Organisation, 2010. Media centre: WHO endorses new rapid tuberculosis test. Available at: http://www.who.int/mediacentre/news/releases/2010/tb-test-20101208/en/ [Accessed October 27, 2015].
31. World Health Organization, 2013. Automated real-time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance: Xpert MTB/RIF assay for the diagnosis of pulmonary and extra-pulmonary TB in adults and children. Policy update, Geneva, Switzerland. Available at: http://apps.who.int/iris/bitstream/10665/112472/1/9789241506335-eng.pdf [Accessed October 27, 2015].
32. World Health Organization, 2014. Global Tuberculosis Report 2014, Geneva, Switzerland. Available at: http://www.who.int/tb/publications/global-report/en/ [Accessed October 27, 2015].
33. World Health Organization, 2002. Guidelines for cost and cost-effectiveness analysis of tuberculosis control, Available at: http://whqlibdoc.who.int/hq/2002/WHO-CDS-TB-2002.305a.pdf?ua=1 [Accessed October 27, 2015].